Apex Labs

Editor's note: This story has been updated to clarify that Kelsi Sheren's treatment does not represent the first legal access to medical psilocybin in Canada.  Health Canada’s Special Access Program (SAP) has authorized a physician to provide Apex Labs’ psilocybin macrodose...

The Canadian biopharma company advancing at-home psilocybin microdose studies and supporting Veteran patients, Apex Labs Ltd., has received Health Canada’s approval for a comprehensive, “statistically powered” macro-and-multi dose advanced psilocybin trial on 160 patients. ...

Biopharma company Apex Labs Ltd. has completed one of the first take-home microdose psilocybin clinical trials, meeting all study endpoints over a two-month period with no adverse events reported. CEO Tyler Powell called it a clinical milestone and said he's certain it will help the...

Apex Labs Ltd., an Iter Investment’s portfolio biopharma company developing psilocybin therapeutics, has been granted approval by Health Canada to begin its large take-home psilocybin clinical trial.  The randomized, double-blind, placebo-controlled Phase 2b study will evaluate the...

Vancouver-based psychedelics biopharma company Apex Labs Ltd. has received Health Canada’s approval to conduct the first North American take-home clinical trial evaluating the safety and efficacy of multiple low doses of self-administered oral synthetic psilocybin compound APEX-52 for the...

For those unaware, Canada provides a legal way for patients presenting unresolved mental health issues to receive psychedelic-assisted treatment. While the country still has not provided legal status to psychedelics, recent amendments have made it possible for health practitioners to request...